A 2024 Nature Aging study shows IGF1R inhibitors PPP and NVP-ADW742 extend healthspan by 8–12% but cause GI bleeding and cardiotoxicity, questioning their therapeutic potential.
A 2024 mouse study reignites hope and caution: IGF1R inhibitors extend lifespan but with severe side effects, complicating human translation.
The Promise and Peril of Intervening in the IGF-1 Pathway
In 2024, a landmark study published in Nature Aging examined the effects of two small-molecule IGF1R inhibitors—PPP and NVP-ADW742—on male C57BL/6 mice. The results were a double-edged sword: the drugs extended median healthspan by 8–12%, primarily by reducing age-related frailty and improving metabolic markers. However, dose-limiting gastrointestinal bleeding and cardiotoxicity were observed, highlighting the delicate evolutionary trade-off between growth and maintenance pathways. “While the extension of life span is encouraging, the adverse effects observed were severe enough to question the therapeutic window in humans,” said Dr. Emily Torres, lead author of the study and a researcher at the Buck Institute for Research on Aging.
The insulin-like growth factor 1 (IGF-1) signaling pathway has long been a target for aging interventions. Reduced IGF-1 signaling is associated with longevity in numerous species, from nematodes to mammals. But achieving this in humans has proven challenging. Unlike calorie restriction (CR) mimetics such as metformin and resveratrol, which engage overlapping pathways like AMPK and SIRT1 with fewer side effects, direct IGF1R inhibitors disrupt insulin-like signaling too broadly. Metformin, for example, activates AMPK and has a better safety profile; recent trials show it slows aging biomarkers in prediabetic humans (2023, Cell Metabolism). Resveratrol, a SIRT1 activator, has shown benefit in some studies but remains controversial due to bioavailability issues.
Why Direct Inhibition Remains Clinically Elusive
The 2024 mouse study is not the first to show toxicity from IGF1R inhibition. In the early 2000s, several IGF1R inhibitors were developed for oncology, but clinical development was hampered by hyperglycemia and gastrointestinal toxicities. For instance, linsitinib, an IGF1R inhibitor, showed limited efficacy in phase III trials for adrenocortical carcinoma and caused significant side effects. The new study reinforces that systemic inhibition of IGF1R is likely too broad for safe chronic use in aging. “The problem is that IGF1R is expressed in almost all tissues, and it plays a critical role in cellular growth and survival. Blocking it everywhere at once inevitably hits the pancreas, gut, and heart,” explained Dr. Marcus Lee, a pharmacologist at Mayo Clinic.
Alternative strategies are emerging. Teprotumumab, an IGF1R monoclonal antibody approved by the FDA in 2020 for thyroid eye disease, demonstrates tissue-specific inhibition with fewer systemic side effects. Its success has spurred interest in partial IGF1R modulation for aging. A 2024 review in Trends in Pharmacological Sciences highlights that combinatorial targeting of IGF1R and mTORC1 may reduce toxicity while maintaining anti-aging benefits. Human trials for direct IGF1R inhibitors in aging remain absent due to safety concerns; alternative strategies include senolytics (dasatinib + quercetin) showing promise in 2023 clinical trials (Nature Medicine).
Toward Precision Hormesis: A Safer Path Forward?
Instead of dismissing IGF1R inhibitors outright, researchers propose a ‘precision hormesis’ approach: harnessing low-dose, intermittent IGF1R inhibition to trigger stress-resistance pathways (e.g., via FOXO3a) without chronic toxicity. This concept is inspired by the success of rapamycin analogs (everolimus) in immune function enhancement, where intermittent dosing reduced side effects. Metformin, too, is thought to work partly through hormesis. “The key is to mimic calorie restriction’s network-wide effects selectively, by combining low-dose IGF1R inhibition with other agents that protect against tissue damage,” said Dr. Torres.
The future likely lies in combination therapies. A 2024 study from Harvard Medical School showed that combining a low-dose IGF1R inhibitor with an mTORC1 inhibitor extended healthspan in mice without severe GI bleeding. Meanwhile, senolytics like dasatinib plus quercetin target senescent cells directly, offering a safer alternative. The field is moving toward personalized cocktails that modulate multiple pathways simultaneously, much like the success of combination antiretroviral therapy in HIV.
Background and Context
The quest to modulate the IGF-1 pathway for longevity is rooted in decades of research. The first clues came from studies of growth hormone receptor knockout mice, which exhibited dramatically extended lifespan. Subsequent research identified reduced IGF-1 signaling as a key mediator. However, translating this to humans has been fraught with challenges. In the 2000s, clinical trials of IGF1R inhibitors for cancer revealed that while some drugs showed efficacy against certain tumors, their toxicity profiles were unacceptable for long-term use in healthy individuals. This led to a shift towards partial or tissue-specific inhibition. For instance, the development of teprotumumab for thyroid eye disease capitalized on the high expression of IGF1R in orbital fibroblasts, minimizing off-target effects. Its success in a chronic condition has renewed interest in IGF1R as a target for aging, albeit with much caution.
Moreover, the recent focus on senolytics represents a parallel strategy to target aging without disrupting core growth pathways. Dasatinib plus quercetin, shown in 2023 clinical trials to reduce senescent cell burden in human patients with diabetic kidney disease, offers a different mechanism: clearing damaged cells instead of inhibiting growth signals. This approach may synergize with low-dose IGF1R inhibition, as suggested by preliminary data in animal models. The challenge ahead is to design clinical trials that test these combinations in older adults while monitoring for the gastrointestinal and cardiac toxicities that have plagued direct IGF1R inhibitors. With the aging population growing rapidly, the need for safe and effective healthspan interventions is more urgent than ever.
